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The aim of this study is to evaluate the rate of axillary recurrences in sentinel lymph node (SLN)-negative breast cancer patients after
sentinel lymph node biopsy (SLNB) alone without further axillary lymph node dissection (ALND). Between May 1999 and February
2002, 333 consecutive patients with primary invasive breast cancer up to 4cm and clinically negative axillae were entered into this
prospective study. Sentinel lymph nodes were identified using the combined method with blue dye (Patent blue V
s) and technetium
99m-labelled albumin (Nanocoll
s). Sentinel lymph nodes were examined by frozen sections, standard haematoxylin and eosin
staining and immunohistochemistry staining. In SLN-positive patients, ALND was performed. Sentinel lymph node-negative patients
had no further ALND. The SLN identification rate was 98.5% (328 out of 333). In all, 128 out of 328 (39.0%) patients had positive
SLNs and complete ALND. A total of 200 out of 328 (61.0%) patients were SLN negative and had no further ALND. The mean
tumour size of SLN-negative patients was 16.5mm. The mean number of SLNs removed was 2.1 per patient. There were no local or
axillary recurrences at a median follow-up of 36 months. The absence of axillary recurrences after SLNB without ALND in SLN-
negative breast cancer patients supports the hypothesis that SLNB is accurate and safe while providing less surgical morbidity than
ALND. Short-term results are very promising that SLNB without ALND in SLN-negative patients is an excellent procedure for
axillary staging in a cohort of breast cancer patients with small tumours.
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Axillary lymph node dissection (ALND) has been the surgical
standard treatment of the axilla for breast cancer patients for
decades and is about to be replaced by sentinel lymph node (SLN)
biopsy (SLNB) for patients with early-stage breast cancer. The
rationales for ALND are the exact staging and prognosis, the
regional control in the axilla and the possibility of survival
improvement (Fisher et al, 1980; Harris and Osteen, 1985; Petrek
and Blackwood, 1995). The extent of the axillary lymph node
involvement is one of the most important independent prognostic
factors for recurrence and survival in patients with invasive breast
cancer (Carter et al, 1989; Rosen et al, 1989, 1993; Rosen and
Groshen, 1990; NIH Consensus Conference, 1991; Mustafa et al,
1998). However, ALND is associated with major problems such as
pain, restriction of arm motion or chronic lymphedema. One of the
most important advances in the surgical treatment of breast cancer
is the introduction of SLNB. Sentinel lymph node biopsy is an
innovative method for axillary staging in breast cancer patients.
Many studies have shown that SLNB can accurately predict axillary
lymph node status. Sentinel lymph node biopsy is a minimally
invasive surgical technique for axillary staging and has the
potential to reduce the morbidity of the surgical procedure (Petrek
et al, 2001; Temple et al, 2002; Peintinger et al, 2003; Schijven et al,
2003). The overall risk of axillary lymph node metastases in
invasive breast cancer is decreasing with the early detection of
small tumours. The increasing frequency of routine mammograms
and the awareness of women leads to the early detection of small
breast carcinomas. The probability of axillary lymph node
involvement in those patients is 30–40% (Lin et al, 1993; Petrek
and Blackwood, 1995; Cady et al, 1996). These patients possibly
could benefit from ALND. The remaining 60–70% with negative
axillary lymph nodes may thus have an unnecessary ALND and
suffer from minor to major short- and long-term morbidity of
ALND. Many studies have shown that SLNB can identify axillary
lymph node involvement in most patients (Krag et al, 1993, 1998;
Giuliano et al, 1994, 1997; O’Hea et al, 1998; Nieweg et al, 2001).
The aim of this study was to evaluate the rate of axillary
recurrences in SLN-negative patients after SLNB alone, without
further ALND.
PATIENTS AND METHODS
A total of 333 consecutive patients with invasive breast carcinomas
was included in this prospective study between May 1999 and
February 2002. Diagnosis of invasive breast carcinoma was
performed by core needle biopsy prior to surgery in all cases. All
patients had clinically negative axillae. Patients, who had in situ
carcinomas, multicentric carcinomas or patients with locally
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axillary lymph nodes were excluded from the study. Informed
consent was obtained from all patients. Patient characteristics are
summarised in Table 1. For the identification of SLNs, the
combined technique using blue dye and radioactive tracer was
performed. Technetium-99m-labelled albumin (Nanocoll
s, Sorin
Biomedica, Saluggia, Italy) was injected peritumorally 16–18h
before surgery at a dose of 30–60MBq by the nuclear medicine
physician if the tumour was palpable. The injection was performed
by ultrasound guidance if the tumour was not palpable. A dynamic
lymphoscintigraphy was performed after injection and before
surgery. The skin overlying the hot spot was marked with a skin
marker. Subareolar subcutaneous injection of 2ml of blue dye
(Patent Blue V
s, Laboratoire Guerbet, Aulnay-sous-Bois, France)
was performed in the operating room after draping of the patient,
and exactly 5min after injection of the blue dye the axillary
incision near the hot spot was performed. Careful and bloodless
dissection was performed to identify the blue lymphatic channels
leading to the blue SLN. Additionally, a gamma probe (C-Trak,
Care Wise, Morgan Hill, CA, USA) was used to identify the hot
SLN. All hot and blue nodes were excised and frozen sections were
made. Subsequently, breast surgery was performed as indicated.
Axillary lymph node dissection was done in the same surgical
procedure if SLNs could not be identified, or if SLNs were positive
for metastases in frozen sections. No further ALND was
performed, if SLNs were negative in frozen sections. If negative
SLNs converted positive in permanent haematoxylin and eosin
(H&E)-stained sections or immunohistochemistry (IHC)-stained
sections, a secondary ALND had to be performed. Sentinel lymph
node biopsy alone, without ALND, was performed exclusively if
SLNs were negative in frozen sections and in H&E-stained slides
and in IHC-stained slides. The histopathologic examination of
SLNs was performed according to the Austrian Pathology Society’s
consensus conference statement. SLNs were cut in 2–3mm slices,
from which 2–3 frozen sections were obtained. Slices were
embedded in paraffin and serially cut in 250mm levels. From each
level, one H&E-stained slide and one IHC-stained slide using
cytokeratin cocktail (AE1/AE3) were examined if the H&E-stained
slide was negative for metastases. Adjuvant treatment of SLN-
negative patients consisted of tamoxifen in most oestrogen
receptor-positive postmenopausal women, and consisted of LHRH
analogues combined with tamoxifen or anastrozole in premeno-
pausal oestrogen receptor-positive patients. Oestrogen receptor-
negative patients received adjuvant chemotherapy. All patients
with breast-conserving surgery received radiotherapy to the whole
breast after surgery, but no radiotherapy was given to the axilla.
Postsurgical follow-up consisted of clinical controls every 3
months in combination with sonography of the breast and the
axilla. Mammograms, X-ray and abdominal sonography were
performed annually.
RESULTS
A total of 333 patients were included in the study. The SLN could
be identified in 328 out of 333 patients, calculating an identifica-
tion rate of 98.5%. SLNs were positive for metastases in 128 out of
328 patients (39.0%). In all, 104 out of 128 patients (81.3%) had
positive SLNs in frozen sections and underwent ALND immedi-
ately after SLNB in the same surgical procedure. In nine out of 128
patients (7.0%) SLNs were negative in frozen sections, but positive
in permanent H&E staining, and in further 15 out of 128 patients
(11.7%) SLNs converted positive in IHC staining. Hence, in 24
patients a secondary ALND had to be performed after receipt of
the final pathological report. That means, 18.7% (24 out of 128) of
all patients with positive SLNs, respectively 10.7% (24 out of 224)
of all patients with primarily negative SLNs, respectively 7.3% (24
out of 328) of all patients, who had a successful SLNB, had to
undergo secondary ALND. In total, 224 out of 328 patients (68.3%)
were SLN negative in frozen sections, but dropped to 215 out of
328 (65.5%) after H&E staining in permanent sections, and totalled
in 200 out of 328 (61.0%) SLN-negative patients after addition of
IHC staining (Table 2). Consecutively, 15 out of 215 patients
(7.0%) converted from negative to positive and were upstaged by
the addition of IHC staining. Exclusively, the 200 patients whose
SLNs were negative in frozen sections and permanent H&E-stained
sections and in IHC staining had SLNB alone without further
ALND. The mean number of SLNs removed was 2.1 per patient and
Table 1 Patients characteristics
SLNB only
(n¼200) %
SLNB+ALND
(n¼128) %
Number of nodes removed
Min 1 7
Max 8 45
Median 2 19
Histology
Invasive ductal carcinoma 178 89.0% 116 90.6%
Invasive lobular carcinoma 22 11.0% 12 9.4%
Tumour size (mm)
Min 1 5
Max 50 55
Range 49 50
Mean 16.5 20.45
Median 15 19
T stage
T1a 7 3.5% 1 0.8%
T1b 24 12.0% 3 2.3%
T1c 118 59.0% 66 51.6%
T2 51 25.5% 57 44.5%
T3 0 1 0.8%
Grading
G1 26 13.0% 4 3.1%
G2 124 62.0% 91 71.1%
G3 50 25.0% 33 25.8%
Hormone receptor status
ER neg/PR neg 27 13.5% 10 7.8%
ER neg/PR pos 2 1.0% 0
ER pos/PR pos 157 78.5% 101 78.9%
ER pos/PR neg 14 7.0% 17 13.3%
Menopausal status
Premenopausal 41 20.5% 40 31.3%
Postmenopausal 159 79.5% 88 68.7%
Table 2 Sentinel lymph node histopathology
n %
Total number of patients 333 100.0%
SLN identification 328/333 98.5%
SLN pos (FS) 104/328
SLN pos (FS and H&E) 113/328
SLN pos (FS, H&E and IHC) 128/328 39.0%
SLN neg (FS) 224/328
SLN neg (FS and H&E) 215/328
SLN neg (FS, H&E and IHC) 200/328 61.0%
FS¼frozen section, H&E¼haematoxylin and eosin staining, IHC¼immuno-
histochemistry staining.
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patient. The SLN was the only positive node in 77 out of 128
patients (60.2%). The mean tumour size was 20.45mm in SLN-
positive patients and 16.5mm in SLN-negative patients. The
median follow-up period was 36 months with a maximum follow-
up time of 56 months and a minimum follow-up time of 22
months. No local or axillary recurrence could be observed in the
200 patients, who underwent SLNB without ALND.
DISCUSSION
The present standard of care for treatment of early-stage invasive
breast cancer is partial or total mastectomy and ALND of levels I
and II, and occasionally of level III. About 30–40% of patients
have positive axillary lymph nodes. The remaining 60–70% of
patients are lymph node negative and may therefore be overtreated
with ALND, with the disadvantage of early and late complications
as seroma, pain, limited arm motion, numbness or lymph oedema
of the arm and breast (Kuehn et al, 2000). Sentinel lymph node
biopsy is a minimally invasive surgical procedure with significant
lower morbidity than ALND (Peintinger et al, 2003; Schijven et al,
2003). The accuracy of SLNB for axillary staging has been
confirmed in many studies (Krag et al, 1993; Giuliano et al,
1994, 1997; Krag et al, 1998; O’Hea et al, 1998; Nieweg et al, 2001).
The long-term outcome of SLNB without ALND has not yet been
evaluated and prospective randomised trials comparing SLNB
alone vs SLNB plus ALND in SLN-negative patients as the
American NSABP-B 32 trial or the European ALMANAC trial are
in the recruitment phase. Few data exist on the local control of
SLNB and there are only a few reports on SLNB alone without
further ALND to date (Giuliano et al, 2000; Roumen et al, 2001;
Schrenk et al, 2001; Chung et al, 2002). Axillary recurrences, as
reported in those studies, range between 0 and 1.4% and follow-up
periods range between 22 and 39 months. A recent study (Chung
et al, 2002) reported on 208 patients with SLNB alone with a
median follow-up of 26 months. In this study, three patients
developed axillary recurrences after a negative SLNB, estimating a
false-negative rate of 1.4%. In this study, 60% of patients received
adjuvant systemic therapy. As nearly all of our patients received
adjuvant sytemic treatment and all patients with breast-conserving
surgery received radiotherapy to the whole breast, but not to the
axilla, it cannot be stated as to what extent adjuvant treatment and
radiotherapy contributed to the negative axillary failure rate in our
group of patients. In our study, we have a median follow-up period
of 36 months and no axillary recurrence could be observed. This
may be a rather short follow-up period, but in a study on outcome
of axillary recurrences after ALND (Newman et al, 2000) a median
time interval of 19 months for local recurrence after ALND is
reported. Axillary recurrence after ALND ranges between 0 and 3%
(Recht and Houlihan, 1995). We could observe no axillary
recurrence in 200 patients with a median follow-up of 36 months
after SLNB only. If we had missed the true SLN and if we had an
unknown false-negative rate, we should have observed 2–12% of
patients (Kjaergaard et al, 1985; Senofsky et al, 1991) with axillary
recurrences, which were 4–24 patients. All of our patients were
SLN negative in frozen sections, H&E and IHC staining. As the
impact of micrometastases identified by IHC is still controversial,
we carried out ALND in all patients with IHC-positive SLNs
according to our protocol. IHC was positive for micrometastases in
15 out of the 328 patients, but we could not find any further
metastases in non-SLNs. A study from the Lee Moffitt Cancer
Center (Jakub et al, 2002) suggested that ALND should be
performed in patients with SLNs positive by CK-IHC only to
reduce the false-negative rate. To date, there is no definite answer
as to how to treat patients with micrometastases in SLNs. ACOSOG
Z0010 will answer the question of micrometastases in SLNs and
bone marrow in the near future.
The results of our study confirm the accuracy of SLNB and SLN-
negative patients with SLNB alone are not at risk for axillary
recurrences in a short-term follow-up. However, as long as
prospective randomised studies are not available, ALND should
not be abandoned as the standard of care for SLN-negative patients.
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